Answers are grounded in this paper and cite their sources.
Results from several microarray-based studies have led to the identification of up-regulated expression levels of the DSG3 gene in pulmonary squamous cell carcinomas (SQCCs). The purpose of this study was to determine the role of DSG3 expression in the diagnosis of SQCCs of the lung and to compare DSG3 with p63, CK5, and CK6, as markers of squamous cell differentiation. Expression of DSG3 mRNA was evaluated in bulk laser capture microdissection-derived microarray data and by quantitative reverse transcription PCR on both SQCCs and adenocarcinomas. Expression levels of p63, CK5, and CK6 were evaluated in microarray data from the same set. An immunohistochemical study using antibodies directed against DSG3, p63, and CK5/6 was also performed. DSG3 was over-expressed in SQCCs but had very limited expression in both adenocarcinomas and non-neoplastic lungs. The microarray data showed that DSG3 had a sensitivity and specificity of 88% and 98%, respectively, in detecting SQCC versus adenocarcinoma. In comparison, sensitivity and specificity was 92% and 82% for p63, and 85% and 96% for CK5, respectively. The correlation coefficient between the microarray and immunohistochemical data for these genes was greater than or equal to 0.9. Using immunohistochemistry, sensitivity and specificity of DSG3 for lung cancers were 98% and 99%, respectively. Therefore, DSG3 can be a useful ancillary marker to separate SQCC from other subtypes of lung cancer. Results from several microarray-based studies have led to the identification of up-regulated expression levels of the DSG3 gene in pulmonary squamous cell carcinomas (SQCCs). The purpose of this study was to determine the role of DSG3 expression in the diagnosis of SQCCs of the lung and to compare DSG3 with p63, CK5, and CK6, as markers of squamous cell differentiation. Expression of DSG3 mRNA was evaluated in bulk laser capture microdissection-derived microarray data and by quantitative reverse transcription PCR on both SQCCs and adenocarcinomas. Expression levels of p63, CK5, and CK6 were evaluated in microarray data from the same set. An immunohistochemical study using antibodies directed against DSG3, p63, and CK5/6 was also performed. DSG3 was over-expressed in SQCCs but had very limited expression in both adenocarcinomas and non-neoplastic lungs. The microarray data showed that DSG3 had a sensitivity and specificity of 88% and 98%, respectively, in detecting SQCC versus adenocarcinoma. In comparison, sensitivity and specificity was 92% and 82% for p63, and 85% and 96% for CK5, respectively. The correlation coefficient between the microarray and immunohistochemical data for these genes was greater than or equal to 0.9. Using immunohistochemistry, sensitivity and specificity of DSG3 for lung cancers were 98% and 99%, respectively. Therefore, DSG3 can be a useful ancillary marker to separate SQCC from other subtypes of lung cancer. Lung cancer is the number one cause of cancer-related death for both men and women worldwide. The high lethality of lung cancer is multifactorial, mainly due to diagnosis at advanced stage and lack of effective therapy. Currently, treatment strategies are predominantly guided by separating lung carcinomas into small cell lung cancer and non-small cell lung cancer. However, non-small cell lung cancer represents a heterogeneous group of cancers, with many histological subtypes. This heterogeneity is also reflected at the molecular level by differences in gene expression1Meyerson M Franklin WA Kelley MJ Molecular classification and molecular genetics of human lung cancers.Semin Oncol. 2004; 31: 4-19Abstract Full Text Full Text PDF PubMed Scopus (73) Google Scholar, 2Potti A Mukherjee S Petersen R Dressman HK Bild A Koontz J Kratzke R Watson MA Kelley M Ginsburg GS West M Harpole Jr, DH Nevins JR A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.N Engl J Med. 2006; 355: 570-580Crossref PubMed Scopus (530) Google Scholar and are likely to affect patient's response to therapy. The advent of novel therapies has started to impact survival.3Gatzemeier U Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer.Oncology (Williston Park). 2003; 17: 7-10PubMed Google Scholar, 4Schallier D Neyns B Fontaine C Steene JV De Mey J Meysman M De Greve J A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).Lung Cancer. 2007; 56: 247-254Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar, 5Tiseo M Loprevite M Ardizzoni A Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.Curr Med Chem Anticancer Agents. 2004; 4: 139-148Crossref PubMed Scopus (71) Google Scholar Indeed, Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (Avastin, Genentech), in combination with a standard platin-based chemotherapy regiment has been shown to improve overall survival and delay the time to progression in patients with advanced non-small cell lung cancer, making Bevacizumab one of the few drugs to significantly impact lung cancer survival.6Sandler A Gray R Perry MC Brahmer J Schiller JH Dowlati A Lilenbaum R Johnson DH Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med. 2006; 355: 2542-2550Crossref PubMed Scopus (5306) Google Scholar, 7Sandler A Herbst R Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.Clin Cancer Res. 2006; 12: 4421s-4425sCrossref PubMed Scopus (69) Google Scholar However, a randomized phase II study conducted by Johnson et al showed some patients with squamous cell carcinoma (SQCC) experienced life-threatening pulmonary hemorrhage.8Johnson DH Fehrenbacher L Novotny WF Herbst RS Nemunaitis JJ Jablons DM Langer CJ DeVore 3rd, RF Gaudreault J Damico LA Holmgren E Kabbinavar F Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.J Clin Oncol. 2004; 22: 2184-2191Crossref PubMed Scopus (1840) Google Scholar These results have even led to the exclusion of SQCC cases from ongoing or new phase III studies.6Sandler A Gray R Perry MC Brahmer J Schiller JH Dowlati A Lilenbaum R Johnson DH Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med. 2006; 355: 2542-2550Crossref PubMed Scopus (5306) Google Scholar Therefore, distinguishing SQCC from other subtypes can be very crucial for making therapeutic decisions. In small biopsy specimens or with more poorly differentiated tumors, distinguishing SQCC from other subtypes can be challenging to the pathologist. In a study by Popp et al, the overall agreement in the final histological subtype was 88.9% for bronchial biopsy alone and for squamous cell carcinoma, 80.5%.9Popp W Rauscher H Ritschka L Redtenbacher S Zwick H Dutz W Diagnostic sensitivity of different techniques in the diagnosis of lung tumors with the flexible fiberoptic bronchoscope. Comparison of brush biopsy, imprint cytology of forceps biopsy, and histology of forceps biopsy.Cancer. 1991; 67: 72-75Crossref PubMed Scopus (96) Google Scholar Further subtyping undifferentiated tumor was considered extremely challenging, with histological agreement for “large” cell carcinoma on biopsy being only 23.1%.9Popp W Rauscher H Ritschka L Redtenbacher S Zwick H Dutz W Diagnostic sensitivity of different techniques in the diagnosis of lung tumors with the flexible fiberoptic bronchoscope. Comparison of brush biopsy, imprint cytology of forceps biopsy, and histology of forceps biopsy.Cancer. 1991; 67: 72-75Crossref PubMed Scopus (96) Google Scholar Unfortunately, only rare markers have reportedly distinguished SQCC from adenocarcinoma (AD). Most often, a combination of cytokeratin (CK) 5/6 and p63 are used. Individually, their sensitivity and specificity for SQCC has a wide range.10Camilo R Capelozzi VL Siqueira SA Del Carlo Bernardi F Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas.Hum Pathol. 2006; 37: 542-546Abstract Full Text Full Text PDF PubMed Scopus (102) Google Scholar, 11Kargi A Gurel D Tuna B The diagnostic value of TTF-1. CK 5/6, and p63 immunostaining in classification of lung carcinomas.Appl Immunohistochem Mol Morphol. 2007; 15: 415-420Crossref PubMed Scopus (157) Google Scholar, 12Li Q Bavikatty N Michael CW The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion.Semin Diagn Pathol. 2006; 23: 15-19Abstract Full Text Full Text PDF PubMed Scopus (23) Google Scholar, 13Pu RT Pang Y Michael CW Utility of WT-1, p63. MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.Diagn Cytopathol. 2008; 36: 20-25Crossref PubMed Scopus (79) Google Scholar, 14Wang BY Gil J Kaufman D Gan L Kohtz DS Burstein DE P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors.Hum Pathol. 2002; 33: 921-926Abstract Full Text Full Text PDF PubMed Scopus (158) Google Scholar A combination of these markers was tested in a small number of lung cancers (total 36 cases) and positivity for both markers was present in only 73% (11/15) of SQCCs, but also in 17% (2/12) of ADs.15Kaufmann O Fietze E Mengs J Dietel M Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.Am J Clin Pathol. 2001; 116: 823-830Crossref PubMed Scopus (253) Google Scholar Kargi et al reported a specificity of 100% but a sensitivity of 69%.11Kargi A Gurel D Tuna B The diagnostic value of TTF-1. CK 5/6, and p63 immunostaining in classification of lung carcinomas.Appl Immunohistochem Mol Morphol. 2007; 15: 415-420Crossref PubMed Scopus (157) Google Scholar Including tumors from different organs, the overall specificity for the combination of the two markers was 96% but with a sensitivity of 77%.15Kaufmann O Fietze E Mengs J Dietel M Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.Am J Clin Pathol. 2001; 116: 823-830Crossref PubMed Scopus (253) Google Scholar Therefore, there likely remains a need to identify markers that would be both more specific and sensitive for the diagnosis of SQCC of the lung. Using a nucleotide microarray data from a previous study on SQCC16Sun Z Yang P Aubry MC Kosari F Endo C Molina J Vasmatzis gene expression survival for patients with squamous cell carcinoma of the Cancer. 2004; PubMed Scopus Google Scholar for genes that were specific to and had antibody that would to a This DSG3 as a for the diagnosis of The purpose of this study was to the overall sensitivity and specificity of DSG3 in SQCC in organs, more in lung cancer. only specimens from were and tumors were to differentiated were only also the sensitivity and specificity of CK5, CK6, and p63 to DSG3 by of laser capture microarray DSG3 was as a marker for differentiating SQCC of the lung from other subtypes by a was using a differential of expression from SQCC from the non-neoplastic lung and from that a specific and sensitive marker would be in SQCC of the in non-neoplastic and or expression in from other this phase data from microarray and differential expression in lung versus non-neoplastic lung was also by reverse transcription to level of of DSG3 as a marker for SQCC of the lung and with other markers was at the mRNA level by microarray An immunohistochemical study was to DSG3 at the The was in a of cancers and were by standard genes for SQCC of the lung were by gene expression data from SQCC from a previous Z Yang P Aubry MC Kosari F Endo C Molina J Vasmatzis gene expression survival for patients with squamous cell carcinoma of the Cancer. 2004; PubMed Scopus Google Scholar genes that had a by in at of these and genes were by this for genes that were in non-neoplastic lung by in at of of non-neoplastic lung by The genes were for specificity using previously DM Kosari F specificity of human genes to 2007; 23: PubMed Scopus Google Scholar this a specificity for a gene on the of that gene in the human had a from to with genes that are specific to pulmonary the number of from SQCC was and the of expression levels of the number of for gene was to the expression level of a gene from the microarray data in the the genes on the high DSG3 was one of the and specific there was a high antibody for DSG3, on the expression of DSG3 in Expression levels of DSG3 were by quantitative in SQCC by and bulk non-neoplastic lung the had to also expression studies by This was with from pulmonary and bulk from of and and bulk specimens of non-neoplastic of for the of DSG3 Expression by or and cell Z Yang P Aubry MC Kosari F Endo C Molina J Vasmatzis gene expression survival for patients with squamous cell carcinoma of the Cancer. 2004; PubMed Scopus Google Scholar SQCC stage stage stage stage SQCC squamous cell were by as in the in a new stage stage stage stage SQCC squamous cell adenocarcinoma. were by as in the of from SQCC or of from non-neoplastic bulk were in III reverse transcription to were on The for DSG3 and as were by standard using of a from the SQCC and reverse for DSG3 were at a final of in the to were for was by for SQCC or by the for The and of the from the were by the and the or by a quantitative PCR on the of of to of DM Kosari F Vasmatzis of laser capture and for gene expression of Mol 2007; PubMed Scopus Google Scholar from were in a two to the were to the from the bulk were by the The and of the from the bulk were by the and a from bulk were to the standard were to expression were by the R determine the for gene of for to p63, CK5, CK6, and The for of the had a at the to at of at Therefore, a of was as the A was using at from to tumors, and carcinoma, from were of cases were and to the exclusion of cases on diagnosis or specimens from were the final number of cases was from different The study was with a antibody to DSG3 on of was by of by treatment in at for was using the with the and squamous cell carcinomas of the lung with high mRNA expression of The was a for the antibody was considered and was to the of the for for and for and of tumor from to in of The was by two and cases by both to a The purpose of this was to determine the correlation between the expression and expression of DSG3, CK5, CK6, and p63, to results and their A of SQCC cases) and cases) in microarray study was by DSG3 immunostaining was and as The other immunohistochemical were on of from the lung tumors using antibodies to CK 5/6 and p63 was in a for were using a using as the The for both CK5/6 and p63 was and the was a for the was to the of the for for and for and of tumor from to in of The of the of the by the of was for marker and was to correlation with the microarray and specificity of DSG3, CK5, CK6, and p63 were by using classification as the of sensitivity and specificity was using the and a Scholar This study was by the and The of as by a of DM Kosari F specificity of human genes to 2007; 23: PubMed Scopus Google Scholar in combination with the bulk squamous microarray Z Yang P Aubry MC Kosari F Endo C Molina J Vasmatzis gene expression survival for patients with squamous cell carcinoma of the Cancer. 2004; PubMed Scopus Google Scholar DSG3 as to high expression in of SQCC expression in of non-neoplastic lung and expression in other by a of greater than expression of DSG3 in SQCC was in the study by quantitative on that both bulk and from both tumor and non-neoplastic and a of DSG3 in as with the non-neoplastic lung. In the lung cancer microarray a high expression of DSG3 in SQCC and a expression of DSG3 in the specificity and sensitivity of p63, CK5, CK6, and DSG3 in SQCC versus on the microarray the sensitive one with the and CK6 the from both the different keratin the sensitivity and specificity for SQCC and was for Expression of was high in SQCCs but also a to high expression of in of had a more specific expression for SQCC the expression of p63 was high in SQCCs, but also to high levels of p63 of DSG3 had a high expression in more than 88% of the SQCCs one of had DSG3 expression the DSG3 alone had a specificity for SQCCs than p63 or and a specificity to p63 and Combining DSG3 and p63 a specificity of 100% with a sensitivity of to these two markers of p63, CK5, CK6, and DSG3 on and specificity were on the expression in and SQCC and specificity were on the expression in and SQCC and and and p63 and cases with gene expression levels the of a of at SQCC cases with gene expression levels the of a of and specificity were on the expression in and SQCC in a new cases with gene expression levels the of a of at SQCC cases with gene expression levels the of a of the of these the microarray results were with the immunohistochemical results in a of these The correlation coefficient for DSG3 and p63 was and at the results for CK5/6 antibody showed a correlation coefficient of with microarray for and only with the correlation between expression in the microarray data and the CK5/6 antibody immunostains was than with only the microarray data were to the specificity and sensitivity for SQCCs with was in these Results of the immunohistochemical study are in SQCCs, DSG3 was and with of to of cases were These cases from lung and and two However, the carcinoma was a cancer and showed squamous by in carcinomas was limited to the of squamous differentiation. The carcinomas had squamous and one was as squamous cell carcinoma of the In the expression of DSG3 present was in the DSG3 expression was present in and expression of DSG3 was and to to in of Results of DSG3 Expression in and of cell SQCC squamous cell small cell in a new Expression of DSG3 in cell squamous cell in a new of Results of DSG3 Expression for to to SQCC squamous cell in a new SQCC squamous cell small cell SQCC squamous cell to to SQCC squamous cell In the of cases of SQCC were for DSG3, only of was cell small cell lung cancer, tumors, and malignant were specificity and sensitivity were as to and 98% to of Results of DSG3 for Lung of lung 98% to to SQCC squamous cell in a new 98% to to SQCC squamous cell In DSG3 to be a sensitive and specific marker for for the lung. In tumors from different DSG3 had a sensitivity of and a specificity of for rare of showed of squamous with the of of the and the expression in these tumors was more was in rare in the DSG3 expression was present in the of the and expression In lung tumors, DSG3 expression very sensitive and was in 98% of SQCCs and in of This sensitivity and specificity is overall than has been previously reported for CK 5/6 and Q Bavikatty N Michael CW The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion.Semin Diagn Pathol. 2006; 23: 15-19Abstract Full Text Full Text PDF PubMed Scopus (23) Google Scholar, O Fietze E Mengs J Dietel M Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.Am J Clin Pathol. 2001; 116: 823-830Crossref PubMed Scopus (253) Google Scholar, M D E J J P63 expression in lung a microarray study of Immunohistochem Mol Morphol. 2004; 12: PubMed Scopus Google Scholar, F C U P A F F A E A E p63 in lung in the of squamous cell Pathol. 2002; PubMed Scopus Google Scholar Indeed, reported sensitivity and specificity for p63 and CK 5/6 have a p63, reported sensitivity between to 100% and specificity from to In the two studies with the number of lung cancers, the reported sensitivity and specificity are than for DSG3 in this M D E J J P63 expression in lung a microarray study of Immunohistochem Mol Morphol. 2004; 12: PubMed Scopus Google Scholar, F C U P A F F A E A E p63 in lung in the of squamous cell Pathol. 2002; PubMed Scopus Google and of CK5/6 and p63 on the Expression in Lung and et F C U P A F F A E A E p63 in lung in the of squamous cell Pathol. 2002; PubMed Scopus Google et BY Gil J Kaufman D Gan L Kohtz DS Burstein DE P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors.Hum Pathol. 2002; 33: 921-926Abstract Full Text Full Text PDF PubMed Scopus (158) Google et O Fietze E Mengs J Dietel M Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.Am J Clin Pathol. 2001; 116: 823-830Crossref PubMed Scopus (253) Google et R Capelozzi VL Siqueira SA Del Carlo Bernardi F Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas.Hum Pathol. 2006; 37: 542-546Abstract Full Text Full Text PDF PubMed Scopus (102) Google et RT Pang Y Michael CW Utility of WT-1, p63. MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.Diagn Cytopathol. 2008; 36: 20-25Crossref PubMed Scopus (79) Google et A Gurel D Tuna B The diagnostic value of TTF-1. CK 5/6, and p63 immunostaining in classification of lung carcinomas.Appl Immunohistochem Mol Morphol. 2007; 15: 415-420Crossref PubMed Scopus (157) Google et M B Gil J E L Gan L Burstein DE p63 and A useful marker for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of J Clin Pathol. 2003; PubMed Scopus Google et Q Bavikatty N Michael CW The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion.Semin Diagn Pathol. 2006; 23: 15-19Abstract Full Text Full Text PDF PubMed Scopus (23) Google et M D E J J P63 expression in lung a microarray study of Immunohistochem Mol Morphol. 2004; 12: PubMed Scopus Google and specificity for p63 and CK5/6 are shown in in a new and specificity for p63 and CK5/6 are shown in CK5/6 and p63, the study by Kaufman et al showed specificity of but the sensitivity was only 77%.15Kaufmann O Fietze E Mengs J Dietel M Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.Am J Clin Pathol. 2001; 116: 823-830Crossref PubMed Scopus (253) Google Scholar the specificity to in a of the sensitivity to However, these were on cancers from organs, only for lung. Kargi et al on lung cancers and reported a specificity of 100% and sensitivity of 82% but their with was small only SQCC and A Gurel D Tuna B The diagnostic value of TTF-1. CK 5/6, and p63 immunostaining in classification of lung carcinomas.Appl Immunohistochem Mol Morphol. 2007; 15: 415-420Crossref PubMed Scopus (157) Google Scholar subtypes as cell quantitative that also a very high expression of DSG3 in SQCCs and DSG3 expression in and non-neoplastic lung. These are by expression studies reported by et Y C M Y S E S H H Y of lung squamous cell carcinoma with different gene expression and prognosis by and PubMed Scopus Google Scholar microarray data a specificity of DSG3 with or p63. and p63 a However, DSG3 and p63 the the specificity to 100% at These results are than reported for the combination of CK5/6 and p63 in the diagnosis of In a et J JH A F J as a factor in lung Pathol. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar that DSG3 was a survival that DSG3 was significantly with a prognosis in both non-small cell lung cancer and However, DSG3 as sensitive and Indeed, DSG3 was to be in of SQCCs and of The in sensitivity of SQCCs with study be by their microarray only one of results showed that DSG3 can be in as as of However, the high DSG3 expression in is more to and from several microarray Y C M Y S E S H H Y of lung squamous cell carcinoma with different gene expression and prognosis by and PubMed Scopus Google Scholar, S Y A M N Petersen expression in human non-small and lung J Cancer. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar, E S A H R J J S H genes in non small cell lung expression of cancer-related genes in squamous cell lung 2004; Full Text Full Text PDF PubMed Scopus Google Scholar and microarray data on lung. expression of DSG3 in would be by Indeed, are one of the of the are and to to and Therefore, their expression is and DSG3 in has role in of as squamous RS and of and other PubMed Scopus Google Scholar, W B MJ expression in the of results in and 2002; 22: PubMed Scopus Google Scholar, J B M Molecular of the Google Scholar The to study are that DSG3 expression by immunohistochemistry was only on and studies at specificity and sensitivity of DSG3, with with CK5/6 and p63, on small biopsy specimens need to be tumors in were at to diagnostic and a standard to specificity and sensitivity of of cell undifferentiated cancers, DSG3 by immunohistochemistry as by mRNA data expression of DSG3 in poorly differentiated cancers also need to be and also to CK 5/6 and p63 microarray data the that other markers role in tumor and In DSG3 is a diagnostic marker to SQCC from other subtypes of lung with with
No takes yet. Share an insight, caveat, or question.
Savci‐Heijink et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: